Back to Search Start Over

Production of Dual Inhibitory Hydrolysate by Enzymatic Hydrolysis of Squid Processing By-product.

Authors :
Liu Q
Yao Y
Ibrahim MAA
Halawany AME
Yang L
Zhang X
Source :
Marine biotechnology (New York, N.Y.) [Mar Biotechnol (NY)] 2022 Apr; Vol. 24 (2), pp. 293-302. Date of Electronic Publication: 2022 Mar 11.
Publication Year :
2022

Abstract

Squid processing by-product contains unutilized abundant proteins. In this study, 6 proteases (pepsin, protamex, trypsin, neutral protease, alkaline protease, and papain) were firstly employed to hydrolyze the squid processing by-product protein. The neutral protease-digested hydrolysate was found to have the most promising ACE (angiotensin-converting enzyme) inhibitory activity. Based on Box-Behnken design, the optimal hydrolysis process was determined to be: 52.4 ℃ of temperature, 5.7 h of time, pH 7.1, and 8151 U/g of enzyme. Under these conditions, the ACE inhibition rate and polypeptide content of the hydrolysate were 84.26% and 229.09 mg/g, respectively. Subsequently, ultrafiltration was performed, and the ACE and renin inhibitory activities of the filtrate (< 1 kDa) were the highest, reaching 87.48 ± 1.76% and 69.72 ± 1.16%, with IC <subscript>50</subscript> values of 1.34 ± 0.12 mg/mL and 1.47 ± 0.06 mg/mL, respectively. However, these activities decreased to 35.15 ± 1.31% and 43.17% ± 1.42%, respectively, after digestion by simulated gastrointestinal juice. Nevertheless, this is the first report representing the neutral protease-digested hydrolysate of squid processing by-product as a potential source of both ACE and renin inhibitors.<br /> (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1436-2236
Volume :
24
Issue :
2
Database :
MEDLINE
Journal :
Marine biotechnology (New York, N.Y.)
Publication Type :
Academic Journal
Accession number :
35275289
Full Text :
https://doi.org/10.1007/s10126-022-10104-4